Abzena will make Faron's drug candidate Clevegen - an antibody that neutralises a subset of immune cells linked to tumor proliferation - at a recently acquired single-use facility in California.
Evotec AG has entered into a non-exclusive license agreement with the MIT’s Broad Institute and Harvard for the use of CRISPR-Cas9 gene editing technology.
As it enters a collaboration to develop environmentally sustainable yet low-cost vaccines, MilliporeSigma says pharma and regulators must look to next-generation technologies for future vaccine development.
Japan's Astellas has agreed to carry out clinical trials of a vaccine for serious diarrhoeal diseases which does not need to be refrigerated or injected and is produced in transgenic rice plants.
Irvine Scientific has launched a medium for neuronal cells for pharmaceutical firms developing regenerative medicines and drugs for central nervous system disorders.
Anglo-American life science firm AMS Biotechnology has launched new cell lines to help companies researching the PD-1/PD-L1 pathway, one of the hottest areas of immuno-oncology research.
Researchers supported by the National Institutes of Health (NIH) have developed a clinical-grade stem cell line, which will help accelerate early-stage clinical research.
Janssen says culture media HyClone Laboratories makes for Celltrion infringe on a US patent covering broths used in the manufacture of Remicade (infliximab).
DNA vaccines are safer and quicker to produce than egg or cell-based products, says VGXI which manufactured material for a recently approved first-in-man study of a Zika vaccine.
Pfizer broke ground on its new Andover, MA-based biologics clinical manufacturing facility this week, which will feature single-use and disposable technologies.
ProteoNic Biotechnology has licensed a vector gene delivery system to Horizon Discovery in a deal it hopes will attract firms looking to eliminate methionine sulphoximine from CHO cell selection processes.
An expansion in Ireland for Eurofins, new cell screening tech for Cyprotex, and an mRNA development deal for Charles River. Welcome to Biopharma-Reporter’s bio-service round-up.
Increased demand for gene therapy services will drive further investment in Lonza's capabilities, the firm says as it inks a strategic deal with Bluebird.
Cobra Biologics has teamed up with Touchlight to test an AAV vector production platform they claim will make manufacturing gene therapies for trials cheaper and faster.
TxCell will develop a CAR-T-based treatment for a rare autoimmune skin disease called bullous pemphigoid in collaboration with researchers at the University of Lubeck in Germany.
India’s first off-the-shelf cell therapy product, StemCells Inc plummets on Phase II trial termination, and Accellta looks to 3D printing. Welcome to Biopharma-Reporter’s stem cell round-up…
Roche’s subcutaneous formulation of MabThera is about reducing the treatment burden for patients and not protecting it from impending biosimilar competition, the firm says.
Thermo Fisher Scientific is to buy FEI Company for $4.2bn saying it will drive adoption of FEI’s technologies among its life sciences customers, particularly in biopharma.
Combination therapies and collaboration will be key in curing cancer, according to Pfizer which has seen 'astounding progress' in its immuno-oncology partnership with Merck KGaA.
EAG has further invested in ABC Laboratories' capacity and analytical capabilities in order to help meet demand for high-end biopharmaceutical analysis.
Ajinomoto Althea has been granted a US patent for a whole antibody crystallization method that is faster at producing stable, biologically-active crystals than current techniques.
Bristol-Myers Squibb (BMS) has completed an expansion of its Devens, MA-based biologics facility to support the company’s growing biologics medicines portfolio.
Daiichi Sankyo has paid Cell Therapy Ltd £12.5m ($18m) for the Japanese rights to its cardiac regeneration candidate Heartcel, made from allogeneic stem cells.
Distance and time differences are not barriers when choosing a biologics CMO, says Goodwin Biotechnology which has won a bispecific antibody process and scale-up contract from Russia’s IBC Generium.
Three deals in the last week signal AbbVie’s strategy in immuno-oncology but are just the latest examples of Big Biopharma’s trend for clinical partnerships.
While there are currently several techniques for producing tissue from heart cells, a new method reduces the amount of cells needed, making it easier and cheaper to replicate.
Triazamacrocyclic lipid complexes increase the efficiency of antibody-drug conjugates (ADCs) by delivering the payload right into the heart of a cancer cell, says BioCellChallenge.
Heptares Therapeutics and Kymab Limited have entered into a strategic collaboration to discover, develop, and commercialize novel antibody therapeutics.
Crown Bioscience has developed humanized mouse cancer models which it claims provide biologic drug developers with an improved means of assessing efficacy.
